Stock listing
NASDAQ:TRXB TRex Bio, Inc. Stock
Home listing (NASDAQ) of TRex Bio, Inc.
Follow TRex Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TRXB
$10.32 USD +0.92 (+9.9%)
Close on Nov 20, 2026
- Day range
- $9.55 – $10.97 USDNov 20, 2026
- Volume
- 92,988 sharesNov 20, 2026
- Market cap
- $283.1M USDAt the close on Nov 20, 2026 · price × 27.45M shares outstanding
- Traded on an average day
- $2.00M USDMedian day 88,700 shares · 1 day with no trades · last 3 months, Oct 8, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TRXB · Home | $10.32 USD | +0.925 (+9.9%) | 92,988 | $9.83 | $10.97 | $9.55 | $9.39 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Oct 8, 2026 – Nov 20, 2026 · NASDAQ:TRXB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.32 | +0.925 | +9.9% | $9.83 | $10.97 | $9.55 | 92,988 | |
| $9.39 | -0.61 | -6.1% | $10.01 | $11.24 | $9.06 | 261,001 | |
| $10.00 | -0.77 | -7.1% | $10.77 | $11.11 | $9.61 | 270,818 | |
| $10.77 | -2.90 | -21.2% | $13.94 | $13.94 | $10.76 | 123,216 | |
| $13.67 | -0.43 | -3.0% | $14.10 | $14.10 | $13.32 | 62,677 | |
| $14.10 | -0.15 | -1.1% | $14.01 | $14.20 | $13.41 | 45,615 | |
| $14.25 | +1.12 | +8.5% | $13.05 | $14.48 | $12.60 | 107,900 | |
| $13.13 | -0.46 | -3.4% | $13.37 | $14.00 | $12.82 | 82,500 | |
| $13.59 | +0.33 | +2.5% | $13.38 | $14.25 | $13.04 | 177,600 | |
| $13.26 | +0.27 | +2.1% | $13.21 | $14.20 | $12.51 | 150,200 | |
| $12.99 | -0.56 | -4.1% | $13.55 | $13.55 | $12.51 | 170,200 | |
| $13.55 | -0.18 | -1.3% | $13.88 | $14.09 | $12.50 | 122,100 | |
| $13.73 | +0.09 | +0.7% | $13.57 | $14.05 | $13.33 | 146,200 | |
| $13.64 | -0.10 | -0.7% | $13.61 | $13.92 | $13.10 | 54,900 | |
| $13.74 | +0.22 | +1.6% | $13.66 | $13.86 | $13.10 | 39,200 | |
| $13.52 | -0.91 | -6.3% | $14.15 | $14.31 | $13.42 | 33,600 | |
| $14.43 | +0.64 | +4.6% | $13.94 | $14.49 | $13.36 | 79,600 | |
| $13.79 | -0.08 | -0.6% | $14.00 | $14.14 | $13.69 | 42,900 | |
| $13.87 | +0.06 | +0.4% | $13.80 | $14.64 | $13.56 | 55,000 | |
| $13.81 | -1.69 | -10.9% | $15.39 | $15.50 | $13.51 | 81,200 | |
| $15.50 | +0.26 | +1.7% | $15.45 | $16.21 | $15.00 | 67,500 | |
| $15.24 | +0.80 | +5.5% | $14.59 | $16.56 | $14.10 | 88,600 | |
| $14.44 | -0.36 | -2.4% | $14.80 | $15.01 | $14.22 | 64,200 | |
| $14.80 | +0.79 | +5.6% | $14.28 | $15.40 | $13.94 | 113,500 | |
| $14.01 | -0.15 | -1.1% | $14.17 | $14.40 | $13.55 | 81,900 | |
| $14.16 | +0.66 | +4.9% | $13.50 | $14.35 | $13.50 | 88,700 | |
| $13.50 | -0.10 | -0.7% | $13.41 | $14.05 | $13.21 | 398,800 | |
| $13.60 | -0.43 | -3.1% | $13.95 | $14.08 | $13.47 | 121,900 | |
| $14.03 | +0.03 | +0.2% | $14.19 | $14.36 | $13.75 | 189,000 | |
| $14.00 | 0.00 | 0.0% | $13.50 | $15.50 | $13.50 | 1,257,000 | |
| $14.00 | — | — | $14.00 | $14.00 | $14.00 | 0 |
- Ticker
- NASDAQ:TRXB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Latest news
TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 13, 2026
Closed $10.77 (-21.2%) on Nov 16, 2026
TRex Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 1 in all · newest Nov 13, 2026 · oldest 2026
Where TRex Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TRXB · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TRXB | BOATS | United States | USD |
Valuation
Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $205.0M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| TRex Bio, Inc. · NASDAQ:TRXB | US$283.1M | US$205.0M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Contineum Therapeutics, Inc. · NASDAQ:CTNM | US$286.1M | US$47.86M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.53 |
| Greenwich LifeSciences, Inc. · NASDAQ:GLSI | US$282.6M | US$276.7M | n/a | n/a | n/a | n/a | n/a | n/a | 2.80 |
| Precision BioSciences, Inc. · NASDAQ:DTIL | US$282.5M | US$228.3M | n/a | 5.1× | n/a | 5.5× | −85.6% | 0.5× | 0.30 |
| AP Biosciences, Inc. · TPEX:6945 | US$282.3M | US$215.7M | n/a | n/a | n/a | 4.0× | n/a | 0.0× | n/a |
| Fulcrum Therapeutics, Inc. · NASDAQ:FULC | US$281.8M | −US$17.87M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.42 |
| Circio Holding ASA · OSL:CRNA | US$281.1M | US$225.9M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | n/a |
| Relmada Therapeutics, Inc. · NASDAQ:RLMD | US$279.5M | US$77.42M | n/a | n/a | n/a | 1.4× | n/a | 0.0× | 1.57 |
| Benitec Biopharma Inc. · NASDAQ:BNTC | US$276.1M | US$99.78M | n/a | n/a | n/a | 1.6× | n/a | 0.0× | 1.46 |
| Galectin Therapeutics Inc. · NASDAQ:GALT | US$271.4M | US$293.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.20 |
| Vicore Pharma Holding AB · OMXSTO:VICO | US$271.1M | US$182.5M | n/a | 467× | n/a | 3.3× | n/a | 0.0× | n/a |
| Median of the others | US$281.5M | US$199.1M | 236× | 2.4× | −85.6% | 0.0× | 1.46 |
Forecasts
4 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 29.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.00 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Brandon Hants | Chief Financial Officer |
| Laura Berner | Chief Operating Officer |
| Carolyn Gabus | Vice President, Clinical Operations |
| Ali Zarrin | Chief Scientific Officer |
| Ariella Kelman | Chief Medical Officer |
| Matt Chrysler | Head of Portfolio & Alliance Management |
| Michael Townsend | Head of Translational Medicine |
Board
| Director | Role |
|---|---|
| Johnston Erwin | Chairman of the Board |
| Carol G. Gallagher | Lead Independent Director |
| Joel S. Marcus | Director |
| Julie Gilmore | Director |
| Mike Ross | Director |
| Peter Hirth | Director |
| Travis Coy | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −21.2% |
IPO
Priced at US$14.00 a share on Oct 8, 2026.
- Price
- US$14.00 a share
- Shares offered
- 8,333,334 shares of common stock
- Offering size
- US$116.7 million
- Underwriters' option
- Up to 1,250,000 more shares
- Listing
- TRXB on the Nasdaq Global Select Market
- Underwriters
- J.P. Morgan, Evercore ISI, Cantor, Stifel, Wedbush PacGrow · In the order on the cover
- Shares delivered
- On or about Oct 13, 2026
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 26, 2026 |
| Filed publicly | Sep 18, 2026 |
| Amended once | Oct 5, 2026 |
| Shares registered with an exchange | Oct 6, 2026 |
| Declared effective by the SEC | Oct 8, 2026 |
| Final prospectus, with the price | Oct 9, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 9, 2026 |
| EFFECT · Notice that a registration is effective | Oct 8, 2026 |
| CERT · Exchange's certificate of listing | Oct 8, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 6, 2026 |
| S-1/A · Registration statement, amended | Oct 5, 2026 |
| S-1 · Registration statement | Sep 18, 2026 |
| DRS/A · Draft registration statement, amended | Aug 21, 2026 |
| DRS/A · Draft registration statement, amended | Jul 31, 2026 |
| DRS · Draft registration statement | Jun 26, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 9, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 39.1M |
| Research and development | 29.8M | 35.0M |
| Selling, general and administrative | 8.04M | 6.50M |
| Operating income | -37.8M | -2.38M |
| Depreciation and amortization | 218.0K | 1.26M |
| EBITDA | -37.6M | -1.12M |
| Income before tax | -34.8M | -444.0K |
| Net income | -34.8M | -3.14M |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 15.2M | 47.5M |
| Short-term investments | 52.5M | 17.8M |
| Current assets | 71.4M | 66.8M |
| Total assets | 73.1M | 68.1M |
| Accounts payable | 371.0K | 527.0K |
| Current liabilities | 4.99M | 7.54M |
| Total liabilities | 165.3M | 126.0M |
| Shareholders' equity | -92.1M | -58.0M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -41.4M | -25.6M |
| Capital spending | -68.0K | -68.0K |
| Free cash flow | -41.4M | -25.6M |
| Cash from financing | 42.1M | 41.9M |
| Change in cash | -32.3M | -1.03M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Oct 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 15, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
All 40 filings
Cap table
Built by 6ix from TRex Bio, Inc.’s releases
- Common shares
- 27,445,682
- Fully diluted
- 27,445,682
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 27,445,682 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 27,445,682 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ali Zarrin | Chief Scientific Officer · Since at least Nov 5, 2026 |
| Ariella Kelman | Chief Medical Officer · Since at least Nov 5, 2026 |
| Brandon Hants | Chief Financial Officer · Since at least Nov 5, 2026 |
| Carol G. Gallagher | Lead Independent Director · Since at least Nov 5, 2026 |
| Carolyn Gabus | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| Joel S. Marcus | Director · Since at least Oct 13, 2026 |
| Johnston Erwin | Chairman of the Board · Since at least Nov 5, 2026 |
| Julie Gilmore | Director · Since at least Nov 5, 2026 |
| Laura Berner | Chief Operating Officer · Since at least Nov 5, 2026 |
| Matt Chrysler | Head of Portfolio & Alliance Management · Since at least Nov 4, 2026 |
All 14 people
| Person | Seat |
|---|---|
| Michael Townsend | Head of Translational Medicine · Since at least Nov 4, 2026 |
| Mike Ross | Director · Since at least Nov 4, 2026 |
| Peter Hirth | Director · Since at least Nov 5, 2026 |
| Travis Coy | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about TRex Bio, Inc.